# Ultragenyx (RARE) — Earnings

RARE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rare/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.90 |
| EPS estimate | −$1.22 |
| EPS surprise | +26.08% |
| Revenue surprise | +16.89% |
| Revenue | $214.0M |
| Revenue estimate | $183.1M |
| Reported | Aug 4, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1515673/000119312526333233/rare-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/0cf112c8-bf50-9ca0-b769-c7f3bf7a9142.html) |

Ultragenyx reported Q2 2026 results on August 4, 2026, with a loss of $0.90 per share against an expected loss of $1.22, a 26.08% beat. Revenue was $214.0 million, well above the $183.1 million estimate. Compared with Q2 2025, the loss narrowed from $1.17 per share and revenue rose about 29% from $166.5 million.

Ultragenyx has reported a loss in all 20 quarters in the table, but losses have generally narrowed as revenue grew. Full-year losses were $10.11 per share in 2022, $8.33 in 2023, $6.34 in 2024 and $5.84 in 2025. Annual revenue rose from $363.2 million in 2022 to $672.7 million in 2025, up about 85%. Q2 2026 set the table's revenue high and its smallest quarterly loss. The first half of 2026 matched the first half of 2025 at a loss of $2.74 per share, on revenue about 15% higher. The company beat EPS estimates in only 7 of the 20 quarters.

Q3 results came out between November 2 and November 5 in each of the past five years, which points to early November 2026 for the next report. It will show whether revenue stays near the $214 million level of Q2.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 4, 2026 | −$1.22 | −$0.90 | 26.08% | $183.1M | $214.0M |
| Q1 2026 | May 5, 2026 | −$1.50 | −$1.84 | -22.93% | $158.4M | $136.0M |
| Q4 2025 | Feb 12, 2026 | −$1.09 | −$1.29 | -18.07% | $198.6M | $207.0M |
| Q3 2025 | Nov 4, 2025 | −$1.23 | −$1.81 | -46.69% | $166.8M | $159.9M |
| Q2 2025 | Aug 5, 2025 | −$1.30 | −$1.17 | 9.81% | $162.0M | $166.5M |
| Q1 2025 | May 6, 2025 | −$1.60 | −$1.57 | 1.74% | $143.8M | $139.3M |
| Q4 2024 | Feb 13, 2025 | −$1.31 | −$1.39 | -6.23% | $151.9M | $164.9M |
| Q3 2024 | Nov 5, 2024 | −$1.48 | −$1.40 | 5.65% | $135.3M | $139.5M |
| Q2 2024 | Aug 1, 2024 | −$1.66 | −$1.52 | 8.47% | $123.2M | $147.0M |
| Q1 2024 | May 2, 2024 | −$1.75 | −$2.03 | -16.19% | $116.0M | $108.8M |
| Q4 2023 | Feb 15, 2024 | −$1.71 | −$1.52 | 10.98% | $119.4M | $127.4M |
| Q3 2023 | Nov 2, 2023 | −$2.08 | −$2.23 | -7.35% | $109.6M | $98.1M |
| Q2 2023 | Aug 3, 2023 | −$2.09 | −$2.25 | -7.63% | $104.8M | $108.3M |
| Q1 2023 | May 4, 2023 | −$1.99 | −$2.33 | -16.95% | $104.7M | $100.5M |
| Q4 2022 | Feb 16, 2023 | −$2.14 | −$2.16 | -1.17% | $105.1M | $103.3M |
| Q3 2022 | Nov 2, 2022 | −$1.81 | −$3.50 | -93.26% | $96.5M | $90.7M |
| Q2 2022 | Jul 28, 2022 | −$1.75 | −$2.26 | -29.11% | $87.8M | $89.3M |
| Q1 2022 | May 5, 2022 | −$1.78 | −$2.19 | -22.96% | $83.7M | $79.9M |
| Q4 2021 | Feb 10, 2022 | −$1.37 | −$1.79 | -30.32% | $83.8M | $83.4M |
| Q3 2021 | Nov 2, 2021 | −$1.39 | −$1.08 | 22.50% | $81.6M | $81.6M |

## Frequently Asked Questions

### When did Ultragenyx (RARE) last report earnings?

Ultragenyx last reported on Aug 4, 2026, covering fiscal Q2 2026.

### Did RARE beat earnings estimates?

Yes. Ultragenyx reported EPS of −$0.90 for Q2 2026 against a −$1.22 estimate — a 26.08% beat.

### How much revenue did RARE report last quarter?

Ultragenyx reported $214.0M in revenue for Q2 2026, against a consensus estimate of $183.1M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).